The AI-powered Epidemiology Database is a comprehensive repository covering 500+ disease indications with 10-year epidemiology forecasts across the seven major markets (US, EU4, UK, and Japan). The platform provides validated, expert-curated epidemiology intelligence enhanced by AI, enabling a deeper understanding of disease burden, detailed epidemiological segmentations, and long-term trends across indications and geographies. Designed to support forecasting, portfolio planning, and commercial strategy, the database delivers decision-ready insights that elevate data-driven business planning for pharmaceutical and healthcare stakeholders.
LAS VEGAS, March 11, 2026 /PRNewswire/ -- DelveEpiAI brings together DelveInsight's curated epidemiology data covering 500+ indications, ranging from major oncology diseases to rare niche orphan conditions. The platform integrates patient population insights along with incidence/prevalence forecasts into a single, easy-to-use interface spanning key markets, including the US, EU4(Italy, Spain, Germany, France), UK, and Japan. By combining DelveInsight's epidemiology expertise with KOL insights, the platform enables users to quickly assess the diagnosed patient pool, explore detailed epidemiological segmentation, and evaluate drug-treated patient populations across multiple indications.

The platform features advanced interactive dashboards that enable teams to visualize comprehensive 7MM epidemiology analysis, compare historical and forecasted patient populations, and explore detailed disease-specific segmentation. Users can analyze diagnosed prevalent and incident populations, demographic breakdowns by age and gender, biomarker-defined cohorts, line of therapy distribution, disease severity, and other customizable disease-specific patient segments.
Designed to support commercial strategy, R&D prioritization, and forecasting excellence, the epidemiology dashboard provides pharma and healthcare organizations with a single, validated source of truth for patient population assessment, incidence and prevalence forecasting, and country-level disease trend intelligence. By transforming complex epidemiology data into actionable insights, the platform empowers teams to make faster, more confident decisions across portfolio planning and market strategy.
Unlock disease burden analysis and global patient population trends for your priority indications with DelveEpiAI at: https://www.delveinsight.com/epidemiology-database
Key Features of DelveInsight's Epidemiology Database DelveEpiAI
Schedule a demo of DelveEpiAI to see how the epidemiology forecasting tool can streamline your internal forecasting, scenario planning, and launch strategy discussions.
Who Uses Epidemiology Databases?
These platforms are widely used by:
Why Choose DelveInsight's Epidemiology Database?
Unlock rapid, AI-powered epidemiological insights with a platform that eliminates the need for time-consuming analysis at the Epidemiology Intelligence Platform
Patient Journey Consulting: We deliver a range of distinctive solutions aimed at transforming healthcare experiences. With deep expertise in patient-centric approaches and extensive industry experience, we understand the subtle complexities of patient needs. By leveraging data-driven insights through advanced analytics, we empower healthcare providers to make informed decisions that improve patient outcomes.
Patient Pool Forecasting: DelveInsight recognizes the complexities pharmaceutical and biotech companies face when estimating and selecting the most suitable patient segments for drug development. Making the right choice is crucial for optimizing outcomes while navigating challenges such as determining the appropriate line of therapy, minimizing patient burden, evaluating diagnostic impact, and projecting drug uptake. DelveInsight provides actionable insights and analytics to support these decisions, enabling companies to target patient populations with the greatest unmet needs, thereby enhancing clinical outcomes and streamlining drug development.
Pharma Consulting Services: Our healthcare consulting services turn complex market data into actionable strategies for pharmaceutical, biotech, and medical device companies. We help clients uncover new revenue streams, assess market potential, and successfully navigate commercialization challenges. With deep expertise in clinical trial design, market intelligence, and strategic consulting, our team partners with clients to optimize decision-making, accelerate innovation pipelines, and improve business outcomes.
Rare Disease Consulting Services: In the rare disease space, one of our fortes, we deliver intelligence that helps clients overcome the unique challenges of niche markets. Our analysts monitor global R&D progress, competitive developments, and shifting regulatory landscapes to provide tailored insights that guide product positioning and investment strategies. From in-depth conference evaluations to detailed competitor analyses, we help clients de-risk decision-making, strengthen portfolios, and efficiently advance therapies from development to market.
Ready to drive your pharma research further, faster? Schedule a call with our expert today!
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/epidemiology-database-delveinsight-unveils-ai-powered-platform-analyzing-patient-burden-and-forecasts-across-500-diseases-302711059.html

Die europäischen Aktienmärkte haben zur Wochenmitte ihre kurze Erholungsphase beendet und sind erneut ins Minus gedreht. Auslöser ist nach Einschätzung von Marktbeobachtern vor allem die wachsende Unsicherheit im Nahen Osten, die über die Energiepreise zunehmend als Belastungsfaktor für die...

Die Panne im E-Voting-System des Kantons Basel-Stadt setzt dem digitalen Abstimmen in der Schweiz vorerst enge Grenzen – aber nicht überall. Nachdem bei der eidgenössischen Volksabstimmung vom 8. März 2026 insgesamt 2048 elektronisch abgegebene Stimmen in Basel-Stadt wegen einer nicht...

Die europäischen Aktienmärkte haben am Donnerstag erneut nachgegeben. Auslöser waren vor allem wieder anziehende Ölpreise und damit verbundene Konjunktursorgen. Marktteilnehmer sehen sich zwischen zwei Extremszenarien gefangen: „Zwischen der Hoffnung auf ein baldiges Kriegsende und einer...

Die Galenica-Tochtergesellschaft Bichsel stellt ihre defizitäre pharmazeutische Produktion bis Ende 2026 ein und richtet ihr Geschäft künftig auf Home-Care-Dienstleistungen aus. Nach Abschluss des gesetzlich vorgesehenen Konsultationsverfahrens mit der Mitarbeitendenvertretung bestätigte der...

Seit Beginn der Luftangriffe der USA und Israels auf den Iran sind nach Angaben des UN-Flüchtlingshilfswerks UNHCR mehr als drei Millionen Menschen innerhalb des Landes vertrieben worden. Betroffen seien zwischen 600.000 und einer Million Haushalte, teilte die Behörde am Donnerstag in Genf...